It is a life sciences private limited company based in New Delhi, Delhi, India, established in 2004.
2004 | New Delhi, Delhi, India | ActiveApex Biotechnologies Private Limited, a active private limited company, was established on 30 September 2004 in New Delhi, Delhi, India. Engaging in biotechnology within the life sciences sector, it holds CIN: U01409DL2004PTC129583. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹0.20 M and a paid-up capital of ₹0.10 M.
It upholds a compliant status. Its leadership includes Ishita Wadia (Director), Ashok Wadia (Director), Gurupreet Sangla (Director). Past directors included Paarth Wadia, Ishita Wadia, Ashok Wadia. It holds no open charges and ₹3.00 Cr settled loans. Its latest AGM occurred on 26 September 2025, with the balance sheet filed on 31 March 2025. It is based at 111, Okhla Industrial Estate Phase-Iii, New Delhi, Delhi, 110020.
U01409DL2004PTC129583
129583
30 September 2004
₹0.20 M
₹0.10 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Apex Biotechnologies Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ishita Wadia | Director | 11 Feb 2023 | Current |
| Ashok Wadia | Director | 28 Jan 2022 | Current |
| Gurupreet Sangla | Director | 28 Jan 2022 | Current |
| Harvinder Singh | Director | 30 Sep 2004 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 28 Sep 2015 | Past |
| Pramod Abcsdd | Additional Director | 24 Sep 2023 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2022 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Apex Biotechnologies Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth dipped by a decrease of 1.27%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2018, Apex Biotechnologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹30,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Dec 2008 | Syndicate Bank | ₹3.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Apex Biotechnologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Apex Biotechnologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apex Biotechnologies's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Apex Biotechnologies Private Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records. was documented.
Apex Biotechnologies Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi. was recorded as a recent event.
Progress on Ishita Wadia was appointed as a Director was appointed as a Director on 11 Feb 2023 & has been associated with this company since 2 years 10 months . was documented.
The activity Ashok Wadia was appointed as a Director was appointed as a Director on 28 Jan 2022 & has been associated with this company since 3 years 10 months . was completed.
Progress on Gurupreet Sangla was appointed as a Director was appointed as a Director on 28 Jan 2022 & has been associated with this company since 3 years 10 months . was documented.
Progress on A charge registered on 27 Dec 2008 via Charge ID 10138854 with Syndicate Bank was fully satisfied on 26 May 2011. was documented.
The CIN of Apex Biotechnologies Private Limited is U01409DL2004PTC129583.
Apex Biotechnologies Private Limited is headquartered at 111, Okhla Industrial Estate Phase-Iii, New Delhi, Delhi, 110020.
Apex Biotechnologies Private Limited was incorporated on 30 September 2004.
The current directors of Apex Biotechnologies Private Limited are
The primary industry of Apex Biotechnologies Private Limited is Life Sciences.
Apex Biotechnologies Private Limited is unlisted.
The authorized capital of Apex Biotechnologies Private Limited is ₹0.20 M, and the paid-up capital is ₹0.10 M.
The compliance status of Apex Biotechnologies Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX